{"id":2149,"date":"2024-12-06T04:26:04","date_gmt":"2024-12-06T04:26:04","guid":{"rendered":"https:\/\/suburban-blog.abymtech.com\/?p=2149"},"modified":"2025-03-05T10:12:57","modified_gmt":"2025-03-05T10:12:57","slug":"immunohistochemistry-markers-in-breast-cancer","status":"publish","type":"post","link":"https:\/\/www.suburbandiagnostics.com\/blog\/immunohistochemistry-markers-in-breast-cancer\/","title":{"rendered":"Immunohistochemistry (IHC) Markers In Breast Cancer"},"content":{"rendered":"

\"\"<\/p>\n

Immunohistochemistry (IHC) is used for diagnostic problems with breast biopsies. IHC is also\u00a0 frequently used as prognostic and predictive tests.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n
IHC Marker(s)<\/b><\/td>\nPurpose<\/b><\/td>\nCell\/ antigen\/ protein targeted<\/b><\/td>\nInterpretation<\/b><\/td>\n<\/tr>\n
ER, PR, Her2<\/td>\nPredictive\/ Theranostic<\/td>\nHormonal markers<\/td>\nImmunohistochemical stains for ER, PR, and HER2 are performed for predictive and therapeutic information.<\/td>\n<\/tr>\n
Ki-67<\/td>\nPrognostic<\/td>\nProliferative index marker<\/td>\nUsed to determine the prognosis of breast cancer. Also seen in differentiating Phyllodes tumour – benign, borderline, and malignant.<\/td>\n<\/tr>\n
P63, Calponin, SMA, S100, HMWCK (high molecular weight cytokeratin)<\/td>\nDiagnostic<\/td>\nMyoepithelial cells<\/td>\nThe presence of myoepithelial cells (MECs) in an intimate relationship with the epithelial cells of the lesion determines the difference between in-situ and invasive disease and between benign pseudo-invasive lesions and invasive carcinoma.<\/p>\n

Also used to categorize various papillary lesions of the breast.<\/td>\n<\/tr>\n

E-cadherin (ECAD)<\/td>\nDiagnostic<\/td>\nCell adhesion molecule<\/td>\nUsed to differentiate between lobular and ductal carcinoma.<\/p>\n
    \n
  • Ductal carcinomas (in-situ or invasive) retain membranous ECAD.<\/li>\n
  • Lobular carcinoma cells lose ECAD staining.<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
Cytokeratin, EGFR<\/td>\nDiagnostic<\/td>\nBasal-like carcinoma<\/td>\nBasal-like carcinomas are triple-negative and show immunoreactivity for basal cytokeratin and EGFR.<\/td>\n<\/tr>\n
Cytokeratin<\/td>\nDiagnostic<\/td>\nSentinel node metastasis<\/td>\nIHC for cytokeratin stains highlight isolated tumour cells (tumour cell aggregates \u22640.2 mm).<\/td>\n<\/tr>\n
EMA, MUC-1<\/td>\nDiagnostic<\/td>\nMicropapillary carcinoma<\/td>\nIdentifying special types of breast carcinomas – micropapillary carcinomas can be confidently identified using EMA (or MUC-1), which demonstrates reverse.<\/td>\n<\/tr>\n
CK7, GCDFP15, Mammaglobin, ER, CK20<\/td>\nDiagnostic<\/td>\nSystemic metastasis of breast carcinoma<\/td>\nIn cases of morphologically similar metastatic tumours, a panel of markers are used to confirm breast primary.<\/td>\n<\/tr>\n
PDL-1<\/td>\nPredictive\/ Theranostic<\/td>\nImmune checkpoint inhibitor<\/td>\nIn triple-negative breast cancer if cells have high expression of PDL1, then immunotherapy can be advised.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Triple-Negative Breast Cancers (ER-negative, PR-negative, HER2-negative):<\/b><\/p>\n